Canada
· Delayed Price · Currency is CAD Optimind Pharma Statistics
Total Valuation
Optimind Pharma has a market cap or net worth of CAD 548,942. The enterprise value is 528,482.
| Market Cap | 548,942 |
| Enterprise Value | 528,482 |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Optimind Pharma has 109.79 million shares outstanding. The number of shares has increased by 16.04% in one year.
| Shares Outstanding | 109.79M |
| Shares Change (YoY) | +16.04% |
| Shares Change (QoQ) | +12.41% |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | n/a |
| Float | 106.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.34 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.48 |
| EV / Sales | 5.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42
| Current Ratio | 0.42 |
| Quick Ratio | 0.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.39 |
Financial Efficiency
Return on equity (ROE) is -1,254.70% and return on invested capital (ROIC) is -63.91%.
| Return on Equity (ROE) | -1,254.70% |
| Return on Assets (ROA) | -43.60% |
| Return on Capital (ROIC) | -63.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.67% in the last 52 weeks. The beta is -0.98, so Optimind Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.98 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 44.46 |
| Average Volume (20 Days) | 2,009 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Optimind Pharma had revenue of CAD 97,735 and -1.09 million in losses. Loss per share was -0.01.
| Revenue | 97,735 |
| Gross Profit | 47,778 |
| Operating Income | -474,801 |
| Pretax Income | -1.10M |
| Net Income | -1.09M |
| EBITDA | n/a |
| EBIT | -474,801 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 146,101 in cash and 125,637 in debt, giving a net cash position of 20,464 or 0.00 per share.
| Cash & Cash Equivalents | 146,101 |
| Total Debt | 125,637 |
| Net Cash | 20,464 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | -226,518 |
| Book Value Per Share | -0.00 |
| Working Capital | -276,518 |
Cash Flow
| Operating Cash Flow | -108,969 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 48.89% |
| Operating Margin | -485.80% |
| Pretax Margin | -1,125.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Optimind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.04% |
| Shareholder Yield | -16.04% |
| Earnings Yield | -209.38% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Optimind Pharma has an Altman Z-Score of -33.48. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.48 |
| Piotroski F-Score | n/a |